Retatrutide
Retatrutide (GLP-1/GIP/Glucagon Triple Receptor Agonist)
The most powerful weight loss compound in clinical trials, activating three hormone receptors to produce an average 24% body weight reduction.
Retatrutide is the most powerful weight loss compound currently being tested in clinical trials. While semaglutide targets one receptor and tirzepatide targets two, retatrutide takes things a step further by activating three different receptor systems at once: GLP-1, GIP, and glucagon. This triple action is why it produces better results than anything else on the market. In Phase 2 trials, participants lost an average of 24.2% of their body weight at the highest dose, and weight was still declining when the study ended, suggesting even greater losses with longer treatment.
To put those numbers in perspective, semaglutide produces around 15% weight loss and tirzepatide around 21%. Retatrutide's 24% average means that a 250-pound person could expect to lose roughly 60 pounds in under a year. Even more striking, 100% of participants at the higher doses lost at least 5% of their body weight, 93% lost at least 10%, and 83% lost at least 15%. These response rates are higher than any other obesity medication ever tested.
Retatrutide was developed by Eli Lilly and is currently in Phase 3 clinical trials, meaning it is not yet available by prescription. If the Phase 3 results confirm what the Phase 2 data showed, it could become the most effective obesity medication on the market, with potential FDA approval projected for late 2026 or 2027. It is administered as a once-weekly injection, similar to semaglutide and tirzepatide.
How It Works
Think of your metabolism as having three separate control panels, each managed by a different hormone receptor. The first panel, GLP-1, controls your appetite. When activated, it tells your brain you are full, slows digestion, and helps your body handle insulin better. This is the same panel that semaglutide targets, and it is the foundation of modern weight loss medications. The second panel, GIP, enhances insulin release and improves how your body processes fat. Tirzepatide already uses both of these panels, which is why it outperforms semaglutide.
What makes retatrutide unique is the third panel: the glucagon receptor. Glucagon is a hormone that tells your body to release stored energy. When this receptor is activated, your liver ramps up fat burning and your body increases its overall energy expenditure. In simple terms, you are not just eating less, you are actually burning more calories even while sitting still. This is a fundamentally different approach from pure appetite suppression, and it explains why the weight loss numbers are so much higher than drugs that only hit one or two receptors.
The combination of all three signals creates a powerful effect: your appetite drops because of GLP-1, your body processes food more efficiently because of GIP, and your metabolism speeds up because of glucagon. Retatrutide is about 9 times more potent at the GIP receptor than your body's natural GIP hormone, though it is only about 40% as potent at the GLP-1 receptor compared to semaglutide. This means appetite suppression may feel somewhat weaker than on semaglutide, but the increased calorie burning from the glucagon component more than makes up the difference. The half-life is approximately 6 days, supporting stable effects with once-weekly dosing.
Potential Benefits
Highest Weight Loss of Any Drug in Trials
At the 12 mg dose, participants lost an average of 24.2% of their body weight over 48 weeks. For a 250-pound person, that translates to roughly 60 pounds lost in under a year, with weight still declining at the end of the study.
Near-Universal Response Rate
At the 8 mg and 12 mg doses, 100% of participants achieved at least 5% weight loss. At 12 mg, 93% lost at least 10% and 83% lost at least 15%. These response rates are higher than any other obesity medication ever tested.
Increased Calorie Burning
Unlike medications that only reduce appetite, retatrutide's glucagon receptor activation causes your body to burn more calories at rest. This means the compound works even when you are not eating, and may help with long-term weight maintenance.
Comprehensive Metabolic Improvement
In trials with type 2 diabetics, retatrutide reduced HbA1c by up to 2.0% while also improving blood pressure, triglycerides, and cholesterol markers, potentially addressing multiple aspects of metabolic syndrome with a single medication.
Once-Weekly Convenience
The half-life of approximately 6 days means you only need to inject once per week for consistent effects throughout the entire week.
What the Research Shows
The landmark Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity and tracked them for 48 weeks. The results set new records for obesity medications. At the 1 mg dose, participants lost 8.7% of body weight. At 4 mg, they lost 17.1%. At 8 mg, they lost 22.8%. And at the highest 12 mg dose, they lost an average of 24.2% of their body weight. At the 12 mg dose, about 63% of participants lost at least 20% of their body weight, and roughly 25% lost 30% or more. Critically, weight was still declining at week 48, meaning longer treatment would likely produce even greater results.
A separate Phase 2 trial for type 2 diabetes, published in The Lancet in 2023, showed that retatrutide produced approximately 17% weight loss at 36 weeks alongside major improvements in blood sugar control, with HbA1c reductions of up to 2.0%. Blood pressure, triglycerides, and cholesterol markers all improved as well. These metabolic benefits suggest retatrutide could address multiple aspects of metabolic syndrome simultaneously rather than requiring separate medications for each condition.
One important finding from the trials was that starting dose matters significantly for tolerability. Participants who started at 2 mg and titrated up slowly experienced far fewer side effects than those who started at 4 mg, with similar weight loss outcomes at 48 weeks. Retatrutide is currently in Phase 3 trials, and if those results confirm the Phase 2 findings, regulatory submission to the FDA is expected around 2026.
What to Know
Nausea is the most common side effect, affecting 25 to 45% of users depending on the dose. Diarrhea, vomiting, constipation, decreased appetite, and feeling overly full are also frequently reported. These effects are dose-dependent and improve significantly with slow titration, particularly when starting at 2 mg rather than 4 mg.
Less common effects include increased heart rate which peaked at week 24 in trials and then declined, injection site reactions, fatigue, and hair thinning related to rapid weight loss rather than the drug itself.
People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use retatrutide. It should be avoided during pregnancy and breastfeeding. Those with a history of pancreatitis, gallbladder disease, type 1 diabetes, diabetic retinopathy, heart rhythm issues, or gastroparesis should use extreme caution and close medical monitoring.
Seek immediate medical attention for persistent vomiting that does not resolve, severe abdominal pain which could indicate pancreatitis or gallbladder issues, signs of allergic reaction such as rash, swelling, or difficulty breathing, or a resting heart rate consistently above 100 beats per minute.
Research References
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. · New England Journal of Medicine · 2023
Landmark Phase 2 trial with 338 adults showing dose-dependent weight loss up to 24.2% at the 12 mg dose over 48 weeks, with 100% of participants at higher doses achieving at least 5% weight loss and 63% losing 20% or more.
View StudyRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias JP, Jastreboff AM, et al. · The Lancet · 2023
Phase 2 trial in type 2 diabetes demonstrating approximately 17% weight loss at 36 weeks alongside HbA1c reductions of up to 2.0%, with improvements in blood pressure, triglycerides, and cholesterol markers.
View StudyA review of an investigational drug retatrutide
Kaur M, Misra S. · European Journal of Clinical Pharmacology · 2024
Comprehensive review of retatrutide's pharmacology, clinical trial data, and potential as a next-generation triple agonist for obesity and type 2 diabetes treatment.
View StudyStructural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Li W, et al. · Cell Discovery · 2024
Structural biology study revealing how retatrutide's molecular design allows it to simultaneously activate three different hormone receptors, explaining its superior efficacy compared to single and dual agonists.
View Study